V
12.51
0.38 (3.13%)
| Previous Close | 12.13 |
| Open | 11.99 |
| Volume | 3,379,933 |
| Avg. Volume (3M) | 1,385,021 |
| Market Cap | 274,102,016 |
| Price / Book | 3.14 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -1.51 |
| Total Debt/Equity (MRQ) | 46.59% |
| Current Ratio (MRQ) | 3.88 |
| Operating Cash Flow (TTM) | -100.26 M |
| Levered Free Cash Flow (TTM) | -61.85 M |
| Return on Assets (TTM) | -55.25% |
| Return on Equity (TTM) | -125.43% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Vor Biopharma Inc. | Bullish | Bullish |
AIStockmoo Score
1.0
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 43.00% |
| % Held by Institutions | 46.77% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 64.00 (Baird, 411.59%) | Buy |
| Median | 36.00 (187.77%) | |
| Low | 9.00 (Wedbush, -28.06%) | Hold |
| Average | 36.25 (189.77%) | |
| Total | 3 Buy, 1 Hold | |
| Avg. Price @ Call | 15.15 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JP Morgan | 19 Dec 2025 | 40.00 (219.74%) | Buy | 12.41 |
| 09 Dec 2025 | 43.00 (243.73%) | Buy | 10.72 | |
| Wedbush | 25 Nov 2025 | 9.00 (-28.06%) | Hold | 7.96 |
| HC Wainwright & Co. | 14 Nov 2025 | 32.00 (155.80%) | Buy | 10.01 |
| 29 Oct 2025 | 52.00 (315.67%) | Buy | 25.50 | |
| Baird | 15 Oct 2025 | 64.00 (411.59%) | Buy | 30.22 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |